Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

Lung cancer remains the leading cause of cancer deaths. Non-small cell lung cancer
(NSCLC) is the most frequent subtype of lung cancer. Surgery, radiation, chemotherapy …

Targeted therapies have revolutionized the treatment and improved the outcome for
oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have …

PURPOSE Overexpression of c-Met protein and epidermal growth factor receptor (EGFR)
mutations can co-occur in non–small-cell lung cancer (NSCLC), providing strong rationale …

Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …

The development of targeted therapies has revolutionized cancer treatment, offering
improved efficacy with reduced side effects compared with traditional chemotherapy. This …

Abstract 50 New drugs including 36 chemical entities and 14 biologics were approved by
the US Food and Drug Administration during 2021. Among the marketed drugs, 31 new …

Precision oncology comprises the set of strategies that aim to design the best cancer
treatment based on tumor biology. A recognized subset of patients with non‐small cell lung …

The therapeutic landscape for patients with advanced malignancies has changed
dramatically over the last twenty years. The growing number of targeted therapies and …

The improved survival outcomes of patients with non-small-cell lung cancer (NSCLC),
largely owing to the improved control of systemic disease provided by immune-checkpoint …